10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADVM (Adverum) Stock Analysis
Buy, Hold or Sell?

Let's analyze Adverum together

I guess you are interested in Adverum Biotechnologies Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Adverum’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Adverum’s Price Targets

I'm going to help you getting a better view of Adverum Biotechnologies Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adverum Biotechnologies Inc

I send you an email if I find something interesting about Adverum Biotechnologies Inc.

1. Quick Overview

1.1. Quick analysis of Adverum (30 sec.)










1.2. What can you expect buying and holding a share of Adverum? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.96
Expected worth in 1 year
$-9.93
How sure are you?
12.5%

+ What do you gain per year?

Total Gains per Share
$-8.97
Return On Investment
-297.0%

For what price can you sell your share?

Current Price per Share
$3.02
Expected price per share
$2.2 - $5.63
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adverum (5 min.)




Live pricePrice per Share (EOD)
$3.02
Intrinsic Value Per Share
$-96.06 - $-40.27
Total Value Per Share
$-97.03 - $-41.24

2.2. Growth of Adverum (5 min.)




Is Adverum growing?

Current yearPrevious yearGrowGrow %
How rich?-$20.2m$134.1m-$78.8m-142.7%

How much money is Adverum making?

Current yearPrevious yearGrowGrow %
Making money-$45.9m-$24.9m-$21m-45.7%
Net Profit Margin-351.8%164.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Adverum (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#810 / 853

Most Revenue
#847 / 853

Most Profit
#753 / 853

Most Efficient
#545 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adverum?

Welcome investor! Adverum's management wants to use your money to grow the business. In return you get a share of Adverum.

First you should know what it really means to hold a share of Adverum. And how you can make/lose money.

Speculation

The Price per Share of Adverum is $3.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adverum.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adverum, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.96. Based on the TTM, the Book Value Change Per Share is $-2.24 per quarter. Based on the YOY, the Book Value Change Per Share is $1.44 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adverum.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.34-77.5%-2.19-72.5%-0.76-25.1%-1.15-38.1%-0.84-27.8%-0.63-20.8%
Usd Book Value Change Per Share-2.22-73.6%-2.24-74.3%1.4447.6%-0.29-9.5%-0.22-7.4%-0.29-9.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.22-73.6%-2.24-74.3%1.4447.6%-0.29-9.5%-0.22-7.4%-0.29-9.6%
Usd Price Per Share2.15-4.55-5.81-3.77-4.31-5.42-
Price to Earnings Ratio-0.23--0.62--1.52--0.87--2.02--3.50-
Price-to-Total Gains Ratio-0.97--2.63--3.37--2.60--5.82--11.22-
Price to Book Ratio-2.23-0.91-0.96-0.76-0.94-1.32-
Price-to-Total Gains Ratio-0.97--2.63--3.37--2.60--5.82--11.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.02
Number of shares331
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.24-0.22
Usd Total Gains Per Share-2.24-0.22
Gains per Quarter (331 shares)-742.25-74.22
Gains per Year (331 shares)-2,968.99-296.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2969-29790-297-307
20-5938-59480-594-604
30-8907-89170-891-901
40-11876-118860-1187-1198
50-14845-148550-1484-1495
60-17814-178240-1781-1792
70-20783-207930-2078-2089
80-23752-237620-2375-2386
90-26721-267310-2672-2683
100-29690-297000-2969-2980

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.050.01.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%5.035.00.012.5%9.039.03.017.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.051.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%5.035.00.012.5%9.039.03.017.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adverum Biotechnologies Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.221-2.242+1%1.436-255%-0.286-87%-0.224-90%-0.289-87%
Book Value Per Share---0.9622.634-137%4.976-119%3.387-128%3.526-127%4.174-123%
Current Ratio--1.5434.167-63%6.418-76%5.220-70%10.004-85%16.418-91%
Debt To Asset Ratio--1.2100.753+61%0.413+193%0.528+129%0.406+198%0.251+383%
Debt To Equity Ratio---1.595-100%0.742-100%1.019-100%0.736-100%0.422-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---26829500.00058970688.000-145%199282696.400-113%125875549.075-121%370720431.445-107%472393736.559-106%
Eps---2.341-2.190-6%-0.759-68%-1.151-51%-0.841-64%-0.629-73%
Ev To Ebitda Ratio--0.138-0.736+634%-1.794+1402%-1.208+977%-3.151+2386%-5.831+4330%
Free Cash Flow Per Share---1.851-1.566-15%-0.713-61%-0.880-52%-0.654-65%-0.461-75%
Free Cash Flow To Equity Per Share---1.845-1.559-15%0.714-358%-0.399-78%-0.249-87%-0.160-91%
Gross Profit Margin--1.0001.129-11%1.112-10%1.080-7%1.048-5%1.024-2%
Intrinsic Value_10Y_max---40.273----------
Intrinsic Value_10Y_min---96.063----------
Intrinsic Value_1Y_max---2.165----------
Intrinsic Value_1Y_min---4.586----------
Intrinsic Value_3Y_max---7.931----------
Intrinsic Value_3Y_min---18.226----------
Intrinsic Value_5Y_max---15.416----------
Intrinsic Value_5Y_min---36.635----------
Market Cap63372284.000+29%45171500.00095544438.000-53%142819696.400-68%101277632.408-55%256537281.445-82%315949811.559-86%
Net Profit Margin----3.5180%1.647-100%-1.2960%-0.7380%-26.7280%
Operating Margin----3.5180%1.780-100%-1.2790%-0.7280%-23.1510%
Operating Ratio---4.582-100%-1.8710%1.757-100%1.015-100%42.393-100%
Pb Ratio-3.138-40%-2.2340.911-345%0.964-332%0.759-394%0.942-337%1.322-269%
Pe Ratio-0.322-40%-0.230-0.620+170%-1.515+560%-0.873+280%-2.017+779%-3.502+1425%
Price Per Share3.020+29%2.1504.553-53%5.813-63%3.775-43%4.312-50%5.418-60%
Price To Free Cash Flow Ratio-0.408-40%-0.290-0.854+194%-1.597+450%-1.036+257%-2.436+739%-4.344+1396%
Price To Total Gains Ratio-1.359-40%-0.968-2.633+172%-3.368+248%-2.601+169%-5.824+502%-11.219+1059%
Quick Ratio--1.4794.241-65%7.580-80%6.455-77%16.222-91%23.209-94%
Return On Assets---0.511-0.326-36%-0.117-77%-0.186-64%-0.144-72%-0.112-78%
Return On Equity----0.7060%-0.2130%-0.3730%-0.2670%-0.1770%
Total Gains Per Share---2.221-2.242+1%1.436-255%-0.286-87%-0.224-90%-0.289-87%
Usd Book Value---20219000.00055258250.000-137%134125000.000-115%119691666.667-117%215929000.000-109%218022825.000-109%
Usd Book Value Change Per Share---2.221-2.242+1%1.436-255%-0.286-87%-0.224-90%-0.289-87%
Usd Book Value Per Share---0.9622.634-137%4.976-119%3.387-128%3.526-127%4.174-123%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---26829500.00058970688.000-145%199282696.400-113%125875549.075-121%370720431.445-107%472393736.559-106%
Usd Eps---2.341-2.190-6%-0.759-68%-1.151-51%-0.841-64%-0.629-73%
Usd Free Cash Flow---38887000.000-32883250.000-15%-22299750.000-43%-26483833.333-32%-28132950.000-28%-20769200.000-47%
Usd Free Cash Flow Per Share---1.851-1.566-15%-0.713-61%-0.880-52%-0.654-65%-0.461-75%
Usd Free Cash Flow To Equity Per Share---1.845-1.559-15%0.714-358%-0.399-78%-0.249-87%-0.160-91%
Usd Market Cap63372284.000+29%45171500.00095544438.000-53%142819696.400-68%101277632.408-55%256537281.445-82%315949811.559-86%
Usd Price Per Share3.020+29%2.1504.553-53%5.813-63%3.775-43%4.312-50%5.418-60%
Usd Profit---49191000.000-45968500.000-7%-24965500.000-49%-34764083.333-29%-35488950.000-28%-27426750.000-44%
Usd Revenue----650000.0000%-900000.0000%-216666.6670%-130000.0000%107475.000-100%
Usd Total Gains Per Share---2.221-2.242+1%1.436-255%-0.286-87%-0.224-90%-0.289-87%
 EOD+6 -2MRQTTM+10 -23YOY+5 -293Y+6 -275Y+6 -2710Y+6 -28

3.3 Fundamental Score

Let's check the fundamental score of Adverum Biotechnologies Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.322
Price to Book Ratio (EOD)Between0-1-3.138
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.479
Current Ratio (MRQ)Greater than11.543
Debt to Asset Ratio (MRQ)Less than11.210
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.511
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Adverum Biotechnologies Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.895
Ma 20Greater thanMa 503.120
Ma 50Greater thanMa 1002.805
Ma 100Greater thanMa 2002.683
OpenGreater thanClose3.070
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Fundamental data was last updated by Penke on 2025-08-23 09:30:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Adverum earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Adverum to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-351.8%+351.8%
TTM-351.8%YOY164.7%-516.5%
TTM-351.8%5Y-73.8%-278.0%
5Y-73.8%10Y-2,672.8%+2,599.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM-351.8%-171.0%-180.8%
YOY164.7%-210.0%+374.7%
3Y-129.6%-289.9%+160.3%
5Y-73.8%-381.1%+307.3%
10Y-2,672.8%-520.3%-2,152.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Adverum is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Adverum to theΒ Biotechnology industry mean.
  • -51.1% Return on Assets means thatΒ Adverum generatedΒ $-0.51 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adverum Biotechnologies Inc:

  • The MRQ is -51.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -32.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-51.1%TTM-32.6%-18.5%
TTM-32.6%YOY-11.7%-20.9%
TTM-32.6%5Y-14.4%-18.2%
5Y-14.4%10Y-11.2%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.1%-11.9%-39.2%
TTM-32.6%-11.9%-20.7%
YOY-11.7%-11.2%-0.5%
3Y-18.6%-12.0%-6.6%
5Y-14.4%-11.7%-2.7%
10Y-11.2%-13.8%+2.6%
4.3.1.3. Return on Equity

Shows how efficient Adverum is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Adverum to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Adverum generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-70.6%+70.6%
TTM-70.6%YOY-21.3%-49.3%
TTM-70.6%5Y-26.7%-43.9%
5Y-26.7%10Y-17.7%-9.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM-70.6%-15.2%-55.4%
YOY-21.3%-15.3%-6.0%
3Y-37.3%-16.9%-20.4%
5Y-26.7%-17.5%-9.2%
10Y-17.7%-19.6%+1.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adverum Biotechnologies Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Adverum is operatingΒ .

  • Measures how much profit Adverum makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Adverum to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-351.8%+351.8%
TTM-351.8%YOY178.0%-529.9%
TTM-351.8%5Y-72.8%-279.1%
5Y-72.8%10Y-2,315.1%+2,242.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM-351.8%-280.2%-71.6%
YOY178.0%-268.7%+446.7%
3Y-127.9%-281.5%+153.6%
5Y-72.8%-350.8%+278.0%
10Y-2,315.1%-530.7%-1,784.4%
4.3.2.2. Operating Ratio

Measures how efficient Adverum is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.582-4.582
TTM4.582YOY-1.871+6.453
TTM4.5825Y1.015+3.566
5Y1.01510Y42.393-41.378
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.952-1.952
TTM4.5822.974+1.608
YOY-1.8713.047-4.918
3Y1.7573.835-2.078
5Y1.0154.924-3.909
10Y42.3936.864+35.529
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adverum Biotechnologies Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adverum is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.54Β means the company has $1.54 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 1.543. The company is able to pay all its short-term debts. +1
  • The TTM is 4.167. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.543TTM4.167-2.623
TTM4.167YOY6.418-2.251
TTM4.1675Y10.004-5.837
5Y10.00410Y16.418-6.414
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5433.480-1.937
TTM4.1673.790+0.377
YOY6.4184.104+2.314
3Y5.2204.609+0.611
5Y10.0045.764+4.240
10Y16.4186.154+10.264
4.4.3.2. Quick Ratio

Measures if Adverum is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Adverum to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.48Β means the company can pay off $1.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 1.479. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 4.241. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.479TTM4.241-2.762
TTM4.241YOY7.580-3.340
TTM4.2415Y16.222-11.981
5Y16.22210Y23.209-6.987
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4792.938-1.459
TTM4.2413.291+0.950
YOY7.5803.928+3.652
3Y6.4554.393+2.062
5Y16.2225.837+10.385
10Y23.2096.549+16.660
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adverum Biotechnologies Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AdverumΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Adverum to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.21Β means that Adverum assets areΒ financed with 121.0% credit (debt) and the remaining percentage (100% - 121.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 1.210. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.753. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.210TTM0.753+0.458
TTM0.753YOY0.413+0.339
TTM0.7535Y0.406+0.346
5Y0.40610Y0.251+0.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2100.339+0.871
TTM0.7530.359+0.394
YOY0.4130.334+0.079
3Y0.5280.341+0.187
5Y0.4060.349+0.057
10Y0.2510.379-0.128
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Adverum is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Adverum to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.595-1.595
TTM1.595YOY0.742+0.853
TTM1.5955Y0.736+0.859
5Y0.73610Y0.422+0.314
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.391-0.391
TTM1.5950.436+1.159
YOY0.7420.436+0.306
3Y1.0190.461+0.558
5Y0.7360.461+0.275
10Y0.4220.514-0.092
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Adverum generates.

  • Above 15 is considered overpriced butΒ always compareΒ Adverum to theΒ Biotechnology industry mean.
  • A PE ratio of -0.23 means the investor is paying $-0.23Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -0.322. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.230. Based on the earnings, the company is expensive. -2
  • The TTM is -0.620. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.322MRQ-0.230-0.093
MRQ-0.230TTM-0.620+0.390
TTM-0.620YOY-1.515+0.896
TTM-0.6205Y-2.017+1.397
5Y-2.01710Y-3.502+1.485
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.322-2.539+2.217
MRQ-0.230-2.361+2.131
TTM-0.620-2.657+2.037
YOY-1.515-3.749+2.234
3Y-0.873-3.883+3.010
5Y-2.017-6.353+4.336
10Y-3.502-7.102+3.600
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -0.408. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.290. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.854. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.408MRQ-0.290-0.118
MRQ-0.290TTM-0.854+0.563
TTM-0.854YOY-1.597+0.743
TTM-0.8545Y-2.436+1.583
5Y-2.43610Y-4.344+1.908
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.408-3.411+3.003
MRQ-0.290-2.951+2.661
TTM-0.854-3.614+2.760
YOY-1.597-4.421+2.824
3Y-1.036-5.258+4.222
5Y-2.436-8.587+6.151
10Y-4.344-9.639+5.295
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Adverum is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -2.23 means the investor is paying $-2.23Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -3.138. Based on the equity, the company is expensive. -2
  • The MRQ is -2.234. Based on the equity, the company is expensive. -2
  • The TTM is 0.911. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-3.138MRQ-2.234-0.904
MRQ-2.234TTM0.911-3.145
TTM0.911YOY0.964-0.052
TTM0.9115Y0.942-0.031
5Y0.94210Y1.322-0.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.1382.206-5.344
MRQ-2.2342.027-4.261
TTM0.9112.194-1.283
YOY0.9642.425-1.461
3Y0.7592.571-1.812
5Y0.9423.805-2.863
10Y1.3224.462-3.140
4.6.2. Total Gains per Share

2.4. Latest News of Adverum Biotechnologies Inc

Does Adverum Biotechnologies Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Adverum Biotechnologies Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-05
22:01
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adverum Biotechnologies Inc.

4.8.1. Institutions holding Adverum Biotechnologies Inc

Institutions are holding 67.491% of the shares of Adverum Biotechnologies Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30BML Capital Management LLC14.57214.9734305752631520911.4943
2025-06-30TCG Crossover Management, LLC8.5620.4412179648200
2025-03-31BlackRock Inc6.80040.00011426855-58427-3.9337
2025-06-30Vanguard Group Inc4.21280883937-145389-14.1247
2025-03-315AM Venture Management, LLC2.58160.895254166600
2025-06-30Goldman Sachs Group Inc2.37010.0002497287364577.9112
2025-03-31Geode Capital Management, LLC2.15070.000245125887681.9815
2025-03-31Pale Fire Capital SE1.75520.19123682675311316.853
2025-03-31State Street Corp1.73470.0001363974-5580-1.5099
2025-03-31Soleus Capital Management, L.P.1.3690.090428724600
2025-06-30Dimensional Fund Advisors, Inc.1.36330.0001286050-1744-0.606
2025-06-30Regeneron Pharmaceuticals Inc0.86220.026218090900
2025-03-31Warren Averett Asset Management, LLC0.76330.00851601651601650
2025-03-31Grant/GrossMendelsohn, LLC()0.76330.25641601577598490.2712
2025-03-31Renaissance Technologies Corp0.76050.00111595692996423.1195
2025-03-31Northern Trust Corp0.71670.0001150372-2205-1.4452
2025-03-31Morgan Stanley - Brokerage Accounts0.3275068717-46071-40.1357
2025-03-31UBS Group AG0.27430.000157548995220.9093
2025-03-31Bank of America Corp0.2441051222764617.5464
2025-03-31Amvescap Plc.0.2375049831498310
Total 52.42136.884510999038+487673+4.4%

4.9.2. Funds holding Adverum Biotechnologies Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Total Stock Mkt Idx Inv2.73430.0001573706-12539-2.1389
2025-05-31Fidelity Small Cap Index1.0260.0019215278-757-0.3504
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.93570.0006196333-89463-31.3031
2025-06-30Fidelity Extended Market Index0.42070.000588263-230-0.2599
2025-01-31Galileo - Biotech Innovation Fund S USD0.33030.99526930300
2025-06-30DFA US Small Cap I0.23160.00074859600
2025-03-31UBC Russell 3000 Index Trust - C0.22360.00114690840323612.3462
2025-07-31Dimensional US Targeted Value ETF0.21480.0014506100
2025-06-30DFA US Targeted Value I0.20890.00074382400
2025-07-31Dimensional US Small Cap ETF0.20480.0014297700
2025-06-30Extended Equity Market Fund K0.18750.000639345-785-1.9561
2025-07-31iShares Micro-Cap ETF0.17480.01053666800
2025-06-30DFA US Micro Cap I0.15070.0013162300
2025-06-30Fidelity Total Market Index0.14070.00012952900
2025-06-30Fidelity Series Total Market Index0.11250.00012360800
2025-03-31NT Col R2000 Val Idx Fd -DC -L -TierFour0.11140.007623375-19778-45.8323
2025-05-31Fidelity Small Cap Value Index0.10830.00392272700
2025-06-30Goldman Sachs Absolute Ret Trckr Instl0.10410.00082185112806141.581
2025-06-30DFA US Core Equity 2 I0.09230.00011936800
2025-06-30NT Ext Equity Mkt Idx Fd - L0.09180.00061925600
Total 7.80481.02811637599-70423-4.3%

5.3. Insider Transactions

Insiders are holding 13.044% of the shares of Adverum Biotechnologies Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-15Laurent FischerSELL91262
2025-05-15Peter SoparkarSELL29602
2025-05-15Setareh SeyedkazemiSELL9242
2025-04-23Braden Michael LeonardBUY500002.98
2025-04-02Braden Michael LeonardBUY152094.04
2025-03-31Braden Michael LeonardBUY195664.38
2025-03-26Braden Michael LeonardBUY204075.04
2025-03-20Braden Michael LeonardBUY306005.61
2025-03-18Braden Michael LeonardBUY623414.69
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Total Stockholder Equity 168,029-23,913144,116-73,40270,714-44,29226,422-46,641-20,219
Net Invested Capital  168,029-23,913144,116-73,40270,714-44,29226,422-46,641-20,219



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets96,179
Total Liabilities116,398
Total Stockholder Equity-20,219
 As reported
Total Liabilities 116,398
Total Stockholder Equity+ -20,219
Total Assets = 96,179

Assets

Total Assets96,179
Total Current Assets48,391
Long-term Assets47,788
Total Current Assets
Cash And Cash Equivalents 42,418
Short-term Investments 1,979
Other Current Assets 3,994
Total Current Assets  (as reported)48,391
Total Current Assets  (calculated)48,391
+/-0
Long-term Assets
Property Plant Equipment 44,340
Long-term Assets Other 1,472
Long-term Assets  (as reported)47,788
Long-term Assets  (calculated)45,812
+/- 1,976

Liabilities & Shareholders' Equity

Total Current Liabilities31,356
Long-term Liabilities85,042
Total Stockholder Equity-20,219
Total Current Liabilities
Short-term Debt 7,363
Accounts payable 4,748
Other Current Liabilities 19,245
Total Current Liabilities  (as reported)31,356
Total Current Liabilities  (calculated)31,356
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt84,858
Long-term Liabilities Other 184
Long-term Liabilities  (as reported)85,042
Long-term Liabilities  (calculated)85,042
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -1,163,161
Accumulated Other Comprehensive Income -451
Other Stockholders Equity 1,143,391
Total Stockholder Equity (as reported)-20,219
Total Stockholder Equity (calculated)-20,219
+/-0
Other
Capital Stock2
Cash and Short Term Investments 44,397
Common Stock Shares Outstanding 21,010
Liabilities and Stockholders Equity 96,179
Net Debt 49,803
Net Invested Capital -20,219
Net Working Capital 17,035
Property Plant and Equipment Gross 63,222
Short Long Term Debt Total 92,221



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
386
0
0
0
1,085
51,613
54,789
167,239
161,906
292,691
283,715
273,829
264,319
252,934
264,345
256,571
234,583
221,929
208,579
198,210
201,905
257,158
246,585
225,907
213,495
221,047
209,884
205,525
222,727
348,599
331,176
507,711
482,567
461,551
526,147
490,581
439,727
407,394
374,955
332,362
308,372
275,577
241,429
196,770
173,010
267,828
253,803
234,375
179,841
137,654
96,179
96,179137,654179,841234,375253,803267,828173,010196,770241,429275,577308,372332,362374,955407,394439,727490,581526,147461,551482,567507,711331,176348,599222,727205,525209,884221,047213,495225,907246,585257,158201,905198,210208,579221,929234,583256,571264,345252,934264,319273,829283,715292,691161,906167,23954,78951,6131,085000386
   > Total Current Assets 
0
0
0
0
822
51,266
52,904
166,333
160,278
291,132
280,632
270,361
260,992
249,229
243,570
235,896
225,274
212,640
199,641
189,523
193,741
249,198
237,922
222,174
208,754
193,137
180,561
167,602
175,870
300,448
282,681
459,700
434,438
409,855
386,272
347,827
317,145
280,117
246,031
213,243
190,595
168,873
147,143
124,596
102,773
199,130
179,418
161,080
131,300
89,469
48,391
48,39189,469131,300161,080179,418199,130102,773124,596147,143168,873190,595213,243246,031280,117317,145347,827386,272409,855434,438459,700282,681300,448175,870167,602180,561193,137208,754222,174237,922249,198193,741189,523199,641212,640225,274235,896243,570249,229260,992270,361280,632291,132160,278166,33352,90451,2668220000
       Cash And Cash Equivalents 
357
0
0
0
564
50,679
52,428
165,329
159,404
290,125
200,537
200,676
259,080
247,082
241,302
231,271
222,170
71,569
39,523
31,713
70,519
152,716
155,451
159,673
154,949
144,107
97,808
73,171
65,897
130,162
27,359
72,696
62,424
45,422
47,299
32,971
34,195
89,652
91,870
84,430
68,431
67,552
111,187
105,366
75,000
149,608
127,321
92,851
60,652
49,161
42,418
42,41849,16160,65292,851127,321149,60875,000105,366111,18767,55268,43184,43091,87089,65234,19532,97147,29945,42262,42472,69627,359130,16265,89773,17197,808144,107154,949159,673155,451152,71670,51931,71339,52371,569222,170231,271241,302247,082259,080200,676200,537290,125159,404165,32952,42850,679564000357
       Short-term Investments 
0
0
0
0
0
0
0
0
0
88,276
79,103
68,210
37,732
37,732
0
0
0
137,934
157,895
154,929
119,966
94,321
79,425
58,209
50,130
45,381
79,834
88,814
100,138
166,904
252,780
381,766
367,305
358,596
316,544
299,734
270,993
181,403
143,971
118,834
117,158
96,733
30,266
11,716
21,526
43,720
46,506
60,390
65,039
33,922
1,979
1,97933,92265,03960,39046,50643,72021,52611,71630,26696,733117,158118,834143,971181,403270,993299,734316,544358,596367,305381,766252,780166,904100,13888,81479,83445,38150,13058,20979,42594,321119,966154,929157,895137,93400037,73237,73268,21079,10388,276000000000
       Net Receivables 
0
0
0
0
8
233
8
8
449
0
0
0
449
1,117
1,029
1,785
886
886
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,196
7,358
5,709
2,457
4,145
155
0
1,351
1,308
0
0
0
6,963
7,116
0
0
0
0007,1166,9630001,3081,35101554,1452,4575,7097,35816,19600000000000000008868861,7851,0291,1174490004498823380000
   > Long-term Assets 
0
0
0
0
263
347
1,885
906
1,628
1,559
3,083
3,468
3,327
3,705
20,775
20,675
9,309
9,289
8,938
8,687
8,164
7,960
8,663
3,733
4,741
27,910
29,323
37,923
46,857
48,151
48,495
48,011
48,129
51,696
139,875
142,754
122,582
127,277
128,924
119,119
117,777
106,704
94,286
72,174
70,237
68,698
74,385
73,295
48,541
48,185
47,788
47,78848,18548,54173,29574,38568,69870,23772,17494,286106,704117,777119,119128,924127,277122,582142,754139,87551,69648,12948,01148,49548,15146,85737,92329,32327,9104,7413,7338,6637,9608,1648,6878,9389,2899,30920,67520,7753,7053,3273,4683,0831,5591,6289061,8853472630000
       Property Plant Equipment 
4
0
0
0
69
107
509
817
1,085
1,421
2,945
3,330
3,187
3,565
3,985
4,335
4,169
4,149
3,798
3,347
3,024
2,820
2,525
2,594
3,586
26,737
28,150
36,760
45,847
47,133
47,477
46,993
47,101
47,423
133,465
137,332
119,060
122,097
121,999
116,461
113,861
102,850
90,328
68,254
67,030
65,526
64,284
62,910
45,218
44,719
44,340
44,34044,71945,21862,91064,28465,52667,03068,25490,328102,850113,861116,461121,999122,097119,060137,332133,46547,42347,10146,99347,47747,13345,84736,76028,15026,7373,5862,5942,5252,8203,0243,3473,7984,1494,1694,3353,9853,5653,1873,3302,9451,4211,085817509107690004
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,650
16,200
5,000
5,000
5,000
5,000
5,000
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000005,0005,0005,0005,0005,0005,0005,00016,20016,65000000000000000
       Other Assets 
0
0
0
0
194
240
1,376
89
543
138
138
138
140
140
16,790
16,340
5,140
5,140
5,140
5,340
5,140
140
1,138
1,139
1,155
1,173
1,173
1,163
1,010
1,018
1,018
1,018
1,028
4,273
6,410
5,422
3,522
5,180
6,925
2,658
3,916
0
3,958
3,920
0
0
0
0
0
0
0
00000003,9203,95803,9162,6586,9255,1803,5225,4226,4104,2731,0281,0181,0181,0181,0101,1631,1731,1731,1551,1391,1381405,1405,3405,1405,1405,14016,34016,790140140138138138543891,3762401940000
> Total Liabilities 
1,383
0
0
0
1,303
1,699
11,751
11,504
12,423
13,011
13,089
11,499
11,727
11,368
16,691
20,341
18,983
20,548
16,399
17,218
17,877
11,115
13,138
10,354
12,328
32,904
32,144
41,311
47,770
44,646
48,613
42,999
48,220
46,731
147,005
144,581
123,542
124,442
130,833
124,025
126,854
117,820
110,274
94,056
89,541
85,540
85,774
90,259
109,127
111,232
116,398
116,398111,232109,12790,25985,77485,54089,54194,056110,274117,820126,854124,025130,833124,442123,542144,581147,00546,73148,22042,99948,61344,64647,77041,31132,14432,90412,32810,35413,13811,11517,87717,21816,39920,54818,98320,34116,69111,36811,72711,49913,08913,01112,42311,50411,7511,6991,3030001,383
   > Total Current Liabilities 
839
0
0
0
1,162
1,608
3,991
4,461
5,471
7,628
7,864
6,496
6,574
5,556
7,897
10,649
9,896
11,966
8,313
9,613
10,674
9,274
11,374
10,065
10,719
10,610
10,149
17,746
19,408
16,767
21,254
16,111
20,871
19,923
20,530
25,326
21,320
23,237
30,620
28,621
32,246
46,472
44,518
28,856
24,914
21,549
22,461
27,657
22,898
25,094
31,356
31,35625,09422,89827,65722,46121,54924,91428,85644,51846,47232,24628,62130,62023,23721,32025,32620,53019,92320,87116,11121,25416,76719,40817,74610,14910,61010,71910,06511,3749,27410,6749,6138,31311,9669,89610,6497,8975,5566,5746,4967,8647,6285,4714,4613,9911,6081,162000839
       Short-term Debt 
0
0
0
0
0
0
1,597
1,995
3,687
2,485
3,331
3,691
4,073
3,404
4,141
5,816
6,547
6,609
5,076
5,948
6,848
6,766
7,356
7,666
0
7,652
7,884
4,044
4,034
8,050
8,442
8,870
8,946
9,024
4,185
8,448
3,772
4,718
12,584
22,472
26,482
26,265
50,792
20,648
10,952
20,984
21,152
10,661
0
7,229
7,363
7,3637,229010,66121,15220,98410,95220,64850,79226,26526,48222,47212,5844,7183,7728,4484,1859,0248,9468,8708,4428,0504,0344,0447,8847,65207,6667,3566,7666,8485,9485,0766,6096,5475,8164,1413,4044,0733,6913,3312,4853,6871,9951,597000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
74
74
74
157
0
0
0
0
3,826
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000100003,8260000157747474740000000000000000
       Accounts payable 
522
0
0
0
769
946
1,576
1,627
951
2,787
1,896
1,141
605
486
2,419
3,067
1,474
3,383
1,125
1,580
1,731
685
2,125
1,736
1,707
1,752
740
3,382
4,103
4,663
10,367
3,034
2,810
2,056
2,259
2,517
1,387
3,245
4,698
846
2,238
2,863
1,418
2,170
1,921
1,897
1,973
2,110
1,610
1,819
4,748
4,7481,8191,6102,1101,9731,8971,9212,1701,4182,8632,2388464,6983,2451,3872,5172,2592,0562,8103,03410,3674,6634,1033,3827401,7521,7071,7362,1256851,7311,5801,1253,3831,4743,0672,4194866051,1411,8962,7879511,6271,576946769000522
       Other Current Liabilities 
317
0
0
0
393
662
1,602
2,021
3,707
2,528
3,655
3,792
5,086
4,011
4,250
5,891
6,572
6,733
5,338
6,183
7,093
7,343
8,496
8,259
9,012
1,206
1,525
10,320
11,271
4,054
2,445
4,207
9,075
8,843
14,086
13,112
14,843
13,842
13,160
5,002
3,272
17,080
-7,763
-8,763
11,839
-1,550
-822
14,886
1,002
16,046
19,245
19,24516,0461,00214,886-822-1,55011,839-8,763-7,76317,0803,2725,00213,16013,84214,84313,11214,0868,8439,0754,2072,4454,05411,27110,3201,5251,2069,0128,2598,4967,3437,0936,1835,3386,7336,5725,8914,2504,0115,0863,7923,6552,5283,7072,0211,602662393000317
   > Long-term Liabilities 
0
0
0
0
141
91
7,760
7,043
6,952
5,383
5,225
5,003
5,153
5,812
8,794
9,692
9,087
8,582
8,086
7,605
7,203
1,841
1,764
289
1,609
22,294
21,995
23,565
28,362
27,879
27,359
26,888
27,349
26,808
126,475
119,255
102,222
101,205
100,213
95,404
94,608
71,348
65,756
65,200
68,565
63,991
63,313
62,602
86,229
86,138
85,042
85,04286,13886,22962,60263,31363,99168,56565,20065,75671,34894,60895,404100,213101,205102,222119,255126,47526,80827,34926,88827,35927,87928,36223,56521,99522,2941,6092891,7641,8417,2037,6058,0868,5829,0879,6928,7945,8125,1535,0035,2255,3836,9527,0437,760911410000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-1,597
-1,995
-3,687
-2,485
-3,331
-3,691
-4,073
-3,404
-4,141
-5,816
-6,547
-6,609
-5,076
-5,948
-6,848
-6,766
-7,356
-7,666
0
18,252
17,862
23,380
28,214
23,728
23,037
22,317
21,762
21,182
125,361
113,917
99,222
97,819
92,901
83,228
80,320
71,348
40,360
54,876
64,084
53,499
52,737
62,602
91,705
85,949
84,858
84,85885,94991,70562,60252,73753,49964,08454,87640,36071,34880,32083,22892,90197,81999,222113,917125,36121,18221,76222,31723,03723,72828,21423,38017,86218,2520-7,666-7,356-6,766-6,848-5,948-5,076-6,609-6,547-5,816-4,141-3,404-4,073-3,691-3,331-2,485-3,687-1,995-1,597000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
373
455
386
370
369
387
481
404
368
187
243
22,294
21,995
23,565
28,362
27,879
27,359
26,888
27,349
1,114
1,114
119,255
102,222
101,205
100,213
95,404
1,047
71,348
65,756
0
0
0
0
0
192
189
184
1841891920000065,75671,3481,04795,404100,213101,205102,222119,2551,1141,11427,34926,88827,35927,87928,36223,56521,99522,29424318736840448138736937038645537300000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
147
7,043
6,952
5,383
5,225
5,003
5,153
5,812
8,421
9,237
8,701
8,212
7,717
7,218
6,722
1,437
1,396
102
1,366
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000001,3661021,3961,4376,7227,2187,7178,2128,7019,2378,4215,8125,1535,0035,2255,3836,9527,043147000000
> Total Stockholder Equity
0
0
0
0
-218
49,914
43,038
155,735
149,483
279,680
270,626
262,330
252,592
241,566
247,654
236,230
215,600
201,381
192,180
180,992
184,028
246,043
233,447
215,553
201,167
188,143
177,740
164,214
174,957
303,953
282,563
464,712
434,347
414,820
379,142
346,000
316,185
282,952
244,122
208,337
181,518
157,757
131,155
102,714
83,469
182,288
168,029
144,116
70,714
26,422
-20,219
-20,21926,42270,714144,116168,029182,28883,469102,714131,155157,757181,518208,337244,122282,952316,185346,000379,142414,820434,347464,712282,563303,953174,957164,214177,740188,143201,167215,553233,447246,043184,028180,992192,180201,381215,600236,230247,654241,566252,592262,330270,626279,680149,483155,73543,03849,914-2180000
   Common Stock
0
0
0
0
0
1
-1,564
2
2
3
3
3
3
3
4
4
4
4
5
5
5
7
6
6
6
6
6
7
7
8
8
10
10
10
10
10
10
10
10
10
10
10
10
10
10
2
2
2
0
2
2
2202221010101010101010101010101010887766666755544443333322-1,564100000
   Retained Earnings Total Equity00000000-863,178-831,6680-769,876-729,745-685,984-648,076-613,667-575,305-530,972-502,536-464,904-437,135-407,935-385,029-366,104-349,986-335,032-320,543-304,884-283,926-265,116-254,062-239,273-225,444-214,014-197,915-175,521-161,220-99,560-84,168-70,074-55,991-46,224-36,715-26,324-18,069000000
   Accumulated Other Comprehensive Income 
0
0
0
0
27
27
26
11
10
-33
12
-3
-11
9
4
-19
-7
-212
-403
-551
-963
-1,021
-908
-854
-799
-754
-738
-745
-725
-833
-598
-605
-261
-316
-417
-523
-714
-1,423
-1,796
-1,953
-1,531
-799
-606
-552
-473
-533
-525
-268
0
-458
-451
-451-4580-268-525-533-473-552-606-799-1,531-1,953-1,796-1,423-714-523-417-316-261-605-598-833-725-745-738-754-799-854-908-1,021-963-551-403-212-7-1949-11-312-3310112627270000
   Capital Surplus 
0
0
0
0
0
0
1,538
182,046
186,186
325,934
326,602
332,404
336,768
341,114
408,866
411,766
413,518
415,603
418,022
420,811
439,048
512,173
518,275
521,285
522,503
523,923
528,458
531,056
560,704
712,713
720,288
930,211
937,134
946,098
954,854
960,180
964,965
970,349
975,653
980,156
0
990,214
994,929
0
0
0
0
0
0
0
0
00000000994,929990,2140980,156975,653970,349964,965960,180954,854946,098937,134930,211720,288712,713560,704531,056528,458523,923522,503521,285518,275512,173439,048420,811418,022415,603413,518411,766408,866341,114336,768332,404326,602325,934186,186182,0461,538000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
632
63,082
1,538
182,046
186,186
325,934
326,602
332,404
336,768
341,114
408,866
411,766
413,518
415,603
418,022
420,811
439,048
512,173
518,275
521,285
522,503
523,923
528,458
531,056
560,704
712,713
720,288
930,211
937,134
946,098
954,854
960,180
964,965
970,349
975,653
980,156
985,651
990,214
994,929
999,319
1,003,709
1,127,383
1,131,592
1,134,556
0
1,140,848
1,143,391
1,143,3911,140,84801,134,5561,131,5921,127,3831,003,709999,319994,929990,214985,651980,156975,653970,349964,965960,180954,854946,098937,134930,211720,288712,713560,704531,056528,458523,923522,503521,285518,275512,173439,048420,811418,022415,603413,518411,766408,866341,114336,768332,404326,602325,934186,186182,0461,53863,0826320000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,000
Cost of Revenue-3,653
Gross Profit-2,653-2,653
 
Operating Income (+$)
Gross Profit-2,653
Operating Expense-140,159
Operating Income-153,159-142,812
 
Operating Expense (+$)
Research Development77,041
Selling General Administrative63,118
Selling And Marketing Expenses0
Operating Expense140,159140,159
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-153,159
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-130,927-175,391
EBIT - interestExpense = -130,927
-130,927
-130,927
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-130,927-130,927
Earnings Before Interest and Taxes (EBITDA)-127,274
 
After tax Income (+$)
Income Before Tax-130,927
Tax Provision-0
Net Income From Continuing Ops-130,927-130,927
Net Income-130,927
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses154,159
Total Other Income/Expenses Net22,2320
 

Technical Analysis of Adverum
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adverum. The general trend of Adverum is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adverum's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Adverum Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adverum Biotechnologies Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.52 < 3.64 < 5.63.

The bearish price targets are: 2.9949 > 2.9297 > 2.2.

Know someone who trades $ADVM? Share this with them.πŸ‘‡

Adverum Biotechnologies Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adverum Biotechnologies Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adverum Biotechnologies Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adverum Biotechnologies Inc. The current macd is 0.11339289.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adverum price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Adverum. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Adverum price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Adverum Biotechnologies Inc Daily Moving Average Convergence/Divergence (MACD) ChartAdverum Biotechnologies Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adverum Biotechnologies Inc. The current adx is 24.60.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Adverum shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Adverum Biotechnologies Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adverum Biotechnologies Inc. The current sar is 3.515504.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Adverum Biotechnologies Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adverum Biotechnologies Inc. The current rsi is 49.90. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Adverum Biotechnologies Inc Daily Relative Strength Index (RSI) ChartAdverum Biotechnologies Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adverum Biotechnologies Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adverum price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Adverum Biotechnologies Inc Daily Stochastic Oscillator ChartAdverum Biotechnologies Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adverum Biotechnologies Inc. The current cci is -39.97510659.

Adverum Biotechnologies Inc Daily Commodity Channel Index (CCI) ChartAdverum Biotechnologies Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adverum Biotechnologies Inc. The current cmo is -10.77098927.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Adverum Biotechnologies Inc Daily Chande Momentum Oscillator (CMO) ChartAdverum Biotechnologies Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adverum Biotechnologies Inc. The current willr is -86.324398.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Adverum Biotechnologies Inc Daily Williams %R ChartAdverum Biotechnologies Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adverum Biotechnologies Inc. The current atr is 0.21754203.

Adverum Biotechnologies Inc Daily Average True Range (ATR) ChartAdverum Biotechnologies Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adverum Biotechnologies Inc. The current obv is -14,248,423.

Adverum Biotechnologies Inc Daily On-Balance Volume (OBV) ChartAdverum Biotechnologies Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adverum Biotechnologies Inc. The current mfi is 41.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Adverum Biotechnologies Inc Daily Money Flow Index (MFI) ChartAdverum Biotechnologies Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adverum Biotechnologies Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Adverum Biotechnologies Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adverum Biotechnologies Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.895
Ma 20Greater thanMa 503.120
Ma 50Greater thanMa 1002.805
Ma 100Greater thanMa 2002.683
OpenGreater thanClose3.070
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Adverum with someone you think should read this too:
  • Are you bullish or bearish on Adverum? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adverum? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adverum Biotechnologies Inc

I send you an email if I find something interesting about Adverum Biotechnologies Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Adverum Biotechnologies Inc.

Receive notifications about Adverum Biotechnologies Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.